WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

Und was bedeutet der Artikel? Staatliche Regulierung?

Hast du den Artikel schon gelesen Summer?

Ich würde etwas kaufen, Was meint ihr?

So einen Rückgang hab ich selten erlebt...

https://finance.sina.cn/hkstock/ggyw/2021-12-15/detail-ikyakumx4292300.d.html?from=wap Der CRO-Sektor beschleunigte seinen Rückgang am Nachmittag...

China's Brii says its COVID-19 antibody cocktail retains activity against Omicron https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-brii-says-its-covid-19-antibody-cocktail-retains-activity-against-omicron-2021-12-13/ ... Although no purchase order for the treatment has been announced, the firm was able to secure manufacturing capacity of 1 million doses for 2022 and 2023 each, Hong said in an investor call, adding it already has about 80,000 doses available in its inventory. Hong said the firm hoped to receive stockpiling orders for the antibody combination. "Those are very important for us as a small company to really manage our cash flow at the same time addressing a public pandemic." The firm, yet to disclose any in-house production capacity for the drug, is partnering with WuXi Biologics (2269 HK) for manufacturing.

New Crown Neutralizing Antibody was approved for listing   ... https://m.sohu.com/a/507666340_223785/?pvid=000115_3w_a ... On December 9, the relevant person in charge of Tengsheng Bo Pharmaceutical stated that WuXi Biologics was entrusted with the production of the above-mentioned drugs, and the production capacity layout would be adjusted according to the supply demand.   ...

Eher allgemeiner gefasst, ein Fall für den Übersetzer und die WuXi wird zumindest erwähnt: CICC: The pharmaceutical sector of Hong Kong stocks enters the bottom area, and the configuration value continues to increase https://m.jrj.com.cn/madapter/hk/2021/12/07195433981558.shtml

<Research Report>Nomura Initiates Coverage on 18 CN Pharmas; Top Picks SBP, Wuxi Bio, Innovent http://www.aastocks.com/en/stocks/news/aafn-news/NOW.1148197/2

M Stanley Foresees WUXI BIO (02269 HK) Shr Rise in 30 Days, Rated Overweight with $175 TP http://www.aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1148046/hk-stock-news Morgan Stanley: To WuXi Biologics (02269) "overweight" rating target price of 175 Hong Kong dollars https://m.jrj.com.cn/madapter/hk/2021/12/07113333979057.shtml

Bin jetzt wieder bei meinem EK angekommen. Überlege gerade aufstocken oder erstmal Geld sichern🤔

Hongkonger Aktien bewegen sich | Pharmaaktien brachen ein, WuXi Biologics (02269) fiel um mehr als 5%, Credit Suisse sagte, die Ergebnisse des Medikamentenkatalogs der Krankenversicherung entsprachen den Erwartungen https://m.jrj.com.cn/madapter/hk/2021/12/06104433972855.shtml

"Research Report" The latest list of major stocks in China and Hong Kong market of Morgan Stanley (table) http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1147234/3 Morgan Stanley issued a report on Chinese stocks strategy and stated that it listed its latest list of focus stocks in the China and Hong Kong market.  ... AIA Shares ... WuXi Biologics (02269 HK) ...

JPMorgan Chase & Co's Long Position In Wuxi Biologics Falls To 6.89% - HKEX Filing https://di.hkex.com.hk/di/NSForm2.aspx?fn=CS20211201E00291&sa2=ns&sid=174136&sd=02/12/2020&ed=02/12/2021&sa1=cl&scsd=02/12/2020&sced=02/12/2021&sc=02269&src=Main&lang=EN&tk=ds

Sehr allgemein und WuXi wird nur kurz erwähnt: https://m.jrj.com.cn/madapter/stock/2021/11/26084433922214.shtml Pharmaceuticals] 2021 three quarterly report summary report: recovery of high growth, medicine enters a long cycle of valuation switching